Navigation Links
GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
Date:1/6/2009

ST. JOSEPH, Mich., Jan. 6 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and high quality manually curated databases for systems biology and pathway analysis, today announced that Bayer Schering Pharma AG has renewed its MetaCore licenses for another three years. Bayer Schering Pharma has programs for cancer, cardiovascular diseases and gynecological therapies and GeneGo has good coverage of these diseases and others. GeneGo is also in the process of building disease specific platforms in cancer and the cardiovascular area that include blueprint pathway maps for the disease, processes and mechanisms as well as offering public domain experimental data and disease ontologies.

"Bayer Schering Pharma was one of our first customers and we appreciate their loyalty," said Julie Bryant, Vice President of Business Development at GeneGo. "MetaCore is widely used in Bayer in multiple departments including bioinformatics, oncology, cardiology and women's health for data mining and analysis of multiple omics experimental data such as gene expression and proteomics."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.1(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.1(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at http://www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology
2. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
3. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
4. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
5. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
6. Unilever Extends Their GeneGo MetaCore License
7. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
8. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
9. GSK Extends GeneGo License and Adds New Products
10. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
11. GeneGo Integrates With Cytoscape
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... and BEIJING , Nov. 30, ... commercial provider of genomic services and solutions with cutting ... that it has completed a USD $75 Million [515 ... Co., Ltd.,s CMB International Capital Management ( Shenzhen ... Management Co., Ltd. ("SDIC Innovation") and Shanghai Sigma Square ...
(Date:11/30/2016)... Mass. , Nov. 30, 2016   Merck ... that it has entered into a set of agreements ... services for Merck,s collection of genetic reagents such as ... with Evotec,s screening expertise offers an accelerated pathway to ... discovery starts with the identification of new targets, a ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... development of a new orally administered treatment for Alzheimer’s disease (AD), today announced ... a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients ...
(Date:11/30/2016)... ... 2016 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), a ... announced that all five of its validated monoclonal antibody (mAb) therapeutic candidates for ... forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated that the ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):